Boston Scientific (BSX) Stock May Be 44% Undervalued As Neuromodulation Growth Builds

Boston Scientific has seen its share price fall sharply over the past year, even as the business pushes deeper into higher end medical devices like neuromodulation. That slide raises a simple question for you as an investor: does the current valuation still line up with the cash the company is expected to generate over time? The stock is down 57.1% over the past year, which puts the focus firmly on whether the recent share price now fully reflects its cash flow profile. Boston Scientific's...